Free Trial

Altimmune (ALT) Competitors

Altimmune logo
$3.70 +0.01 (+0.14%)
As of 12:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALT vs. PGEN, ETNB, XERS, ABCL, EVO, COLL, NTLA, CVAC, ELVN, and CALT

Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Precigen (PGEN), 89BIO (ETNB), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), CureVac (CVAC), Enliven Therapeutics (ELVN), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

Altimmune vs. Its Competitors

Precigen (NASDAQ:PGEN) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Precigen presently has a consensus price target of $8.25, suggesting a potential upside of 115.12%. Altimmune has a consensus price target of $17.40, suggesting a potential upside of 370.91%. Given Altimmune's higher probable upside, analysts clearly believe Altimmune is more favorable than Precigen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precigen
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Altimmune
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Altimmune has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precigen$4.34M263.30-$126.24M-$0.42-9.13
Altimmune$20K16,306.04-$95.06M-$1.18-3.13

In the previous week, Altimmune had 23 more articles in the media than Precigen. MarketBeat recorded 31 mentions for Altimmune and 8 mentions for Precigen. Precigen's average media sentiment score of 1.53 beat Altimmune's score of 0.30 indicating that Precigen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Precigen
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Altimmune
3 Very Positive mention(s)
5 Positive mention(s)
21 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

33.5% of Precigen shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 47.1% of Precigen shares are held by insiders. Comparatively, 4.4% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Precigen has a net margin of -2,868.66% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat Precigen's return on equity.

Company Net Margins Return on Equity Return on Assets
Precigen-2,868.66% -842.83% -78.98%
Altimmune -438,730.03%-62.63%-55.29%

Precigen has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Summary

Altimmune beats Precigen on 9 of the 16 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALT vs. The Competition

MetricAltimmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$326.39M$2.54B$5.77B$10.15B
Dividend YieldN/A56.65%5.69%4.61%
P/E Ratio-3.1323.4374.4425.99
Price / Sales16,306.04556.98465.6391.46
Price / CashN/A169.2537.0859.91
Price / Book2.125.3512.216.30
Net Income-$95.06M$32.95M$3.28B$270.75M
7 Day Performance-2.25%1.85%1.21%3.36%
1 Month Performance2.07%9.09%7.52%6.51%
1 Year Performance-47.96%0.91%63.84%27.98%

Altimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALT
Altimmune
2.5849 of 5 stars
$3.70
+0.1%
$17.40
+370.9%
-48.5%$326.39M$20K-3.1350
PGEN
Precigen
4.5885 of 5 stars
$4.51
-0.9%
$8.25
+82.9%
+325.5%$1.34B$3.92M-10.74190Positive News
ETNB
89BIO
2.6663 of 5 stars
$9.03
-4.1%
$26.63
+194.9%
+6.7%$1.34BN/A-2.5040Positive News
XERS
Xeris Biopharma
3.0652 of 5 stars
$7.83
-0.9%
$7.08
-9.5%
+168.5%$1.26B$203.07M-37.28290Positive News
ABCL
AbCellera Biologics
2.4588 of 5 stars
$4.18
-2.8%
$8.00
+91.4%
+71.4%$1.25B$32.88M-7.60500
EVO
Evotec
1.7053 of 5 stars
$3.50
-0.3%
$5.40
+54.3%
+1.5%$1.24B$777.33M0.004,827
COLL
Collegium Pharmaceutical
3.5233 of 5 stars
$38.80
+1.2%
$42.33
+9.1%
+7.9%$1.22B$631.45M37.31210Positive News
NTLA
Intellia Therapeutics
4.3436 of 5 stars
$11.35
-2.2%
$29.05
+156.0%
-43.6%$1.22B$57.88M-2.42600Analyst Revision
CVAC
CureVac
3.9367 of 5 stars
$5.37
flat
$6.83
+27.3%
+77.9%$1.20B$510.51M5.59880Short Interest ↑
ELVN
Enliven Therapeutics
3.0471 of 5 stars
$20.27
-0.4%
$41.20
+103.3%
-13.7%$1.20BN/A-10.1450Positive News
Insider Trade
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180News Coverage

Related Companies and Tools


This page (NASDAQ:ALT) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners